Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.

The Journal of rheumatology - 1 Jan 2009

Askanase Anca D, Wallace Daniel J, Weisman Michael H, Tseng Chung-E, Bernstein Lana, Belmont H Michael, Seidman Ernest, Ishimori Mariko, Izmirly Peter M, Buyon Jill P

Abstract excerpt

OBJECTIVE: Individualized therapy based on genetic background and monitoring of metabolites can optimize drug safety and efficacy. Such an approach is available for azathioprine (AZA), the thiopurine antimetabolite. AZA exerts therapeutic effects when metabolized to the active thiopurine nucleotide, 6-thioguanine (6-TGN). In inflammatory bowel disease (IBD), 6-TGN levels in the target range of 235-400...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Lupus Erythematosus, Systemic

Share to Methyltransferases

Share to Patient Compliance

Share to Pharmacogenetics

Share to Thioguanine

Source

Identifiers

PMID: 19040311
DOI: 10.3899/jrheum.070968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.PMID 19040311Read ↗

Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.Semantic proximity Read ↗

Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel diseaseSemantic proximity Read ↗

Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.Semantic proximity Read ↗

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.Semantic proximity Read ↗

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.Semantic proximity Read ↗

On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.Semantic proximity Read ↗

Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.Semantic proximity Read ↗

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

Pharmacological monitoring of azathioprine therapy.Semantic proximity Read ↗

[Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].Semantic proximity Read ↗

Personalization of thiopurine therapy: Current recommendations and future perspectives.Semantic proximity Read ↗

Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.